RNA Technologies Expand Tool Kit for Cancer Immunotherapy
Elie Dolgin • October 1, 2019
Multiple companies are pursuing mRNA-based medicines that harness the body's protein-making machinery to transform lab-synthesized nucleotides into cancer-associated antigens, in the case of vaccines, or immune-stimulating molecules, in the case of therapeutics. Several candidates from BioNTech and Moderna have shown promise in early-stage testing.
Continue reading at Cancer Discovery.
As humans return to the Moon, researchers are trying to understand—and thwart—the biological toll of deep-space radiation.
Animals that researchers call “supersucklers” come back for their mother’s milk even after they can hunt, mate and fend for themselves.